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Neonatal AAV9-gene therapy of the lysosomal enzyme galac-
tosylceramidase (GALC) significantly ameliorates central and
peripheral neuropathology, prolongs survival, and largely
normalizes motor deficits in Twitcher mice. Despite these
therapeutic milestones, new observations identified the pres-
ence of multiple small focal demyelinating areas in the brain
after 6–8 months. These lesions are in stark contrast to the
diffuse, global demyelination that affects the brain of naive
Twitcher mice. Late-onset lesions exhibited lysosomal alter-
ations with reduced expression of GALC and increased psy-
chosine levels. Furthermore, we found that lesions were
closely associated with the extravasation of plasma fibrinogen
and activation of the fibrinogen-BMP-SMAD-GFAP gliotic
response. Extravasation of fibrinogen correlated with tight
junction disruptions of the vasculature within the lesioned
areas. The lesions were surrounded by normal appearing
white matter. Our study shows that the dysregulation of ther-
apeutic GALC was likely driven by the exhaustion of thera-
peutic AAV episomal DNA within the lesions, paralleling
the presence of proliferating oligodendrocyte progenitors
and glia. We believe that this is the first demonstration of di-
minishing expression in vivo from an AAV gene therapy vec-
tor with detrimental effects in the brain of a lysosomal storage
disease animal model. The development of this phenotype
linking localized loss of GALC activity with relapsing
neuropathology in the adult brain of neonatally AAV-gene
therapy-treated Twitcher mice identifies and alerts to possible
late-onset reductions of AAV efficacy, with implications to
other genetic leukodystrophies.
INTRODUCTION
Globoid cell leukodystrophy, or Krabbe disease (KD), is a lysosomal
storage disorder caused by the loss of function of the lysosomal
enzyme galactosylceramidase (GALC),1 resulting in the abnormal
accumulation of the GALC substrate psychosine.2–4 Most affected
patients are newborns developing diffuse central and peripheral scle-
rosis (demyelination),5 with neurosensory deficits and muscle atro-
phy, leading to death within the first few years of life.6
Recent efforts have focused on the development of gene therapy
protocols that aim to replace the deficient GALC enzyme. Previous
studies have been successful in delaying the onset of demyelin-
ation, motor deficits, and significantly prolonging survival.7–14 A
study published by our group used a high-dose gene therapy
regimen with codon-optimized murine Galc packaged in an ad-
eno-associated virus, serotype 9 capsid (AAV9-GALC) and globally
delivered via intracranial (i.c.), intrathecal (i.t.), and intravenous
(i.v.) injections in the Twitcher (TWI) mouse model of KD.
Treated TWI mice showed few to no signs of disease for most
of their lifespan, which was significantly lengthened from a
44-day median survival to 265 days, with maximal survival of
650 days.7
We investigated the factors influencing the long-term survival of
AAV9-GALC treated TWI and we determined that there is a late-
onset manifestation of the sclerotic phenotype, which is limited to
small and well-defined portions in the brain. Instead of the diffuse
demyelination traditionally observed in the brain of untreated
TWI, multiple focal lesions of demyelination engulfed by gliotic
scarring were found in brain white matter. These lesions exhibited
a localized neuroinflammatory state featuring the proliferation of
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oligodendrocyte progenitor cells (OPCs), astrocytes, and microglia.
Expression of the GALC transgene declined in the lesions and was
accompanied by increased levels of psychosine. Analysis of treated
TWI animals at a younger age (i.e., 40 days of age) did not reveal
any evidence of focal demyelinating lesions, indicating that this
phenotype arises as a late-onset phenomenon.
Figure 1. Multi-focal lesions in the brain of aged TWI
treated with AAV9-GALC
(A–D) MBP-stained sagittal whole-brain scans of P40 WT
(A), sham P40 TWI (B), aged TWI+AAV (C), and aged
TWI+AAV+BMT (D). In both TWI+AAV (C) and TWI+
AAV+BMT (D), multi-focal demyelinating lesions were
observed. Tissue adjacent to the lateral ventricle (arrows)
was affected in all aged animals examined; brainstem (ar-
rowheads), corpus callosum, and cerebellum were also
commonly affected. (E–H) Higher-magnification images of
MBP-stained P40 WT (E), sham P40 TWI (F), P40 TWI+
AAV (G), and P40 TWI+AAV+BMT (H). At this age, neither
TWI+AAV nor TWI+AAV+BMT animals display any demy-
elinating lesions. (I–K) Higher-magnification images of
MBP-stained aged WT (I), aged TWI+AAV (J), and aged
TWI+AAV+BMT (K). The demyelinating lesions are evident
in the stria terminals near the lateral ventricle (arrows) and
corpus callosum (arrowheads). (L–O) Electron microscopy
imaging was used to examine myelin structure between
agedWT (L), sham P40 TWI (M), P40 TWI+AAV (N), and an
aged TWI+AAV (O). No evidence of demyelination was
detected in P40 TWI+AAV at P40 (N), displaying similar
structure to aWT animal (L). Areas of demyelination in aged
TWI+AAV (O) were similar in appearance to the diffuse
demyelination seen in sham TWI (M); however, the damage
was localized and displayed sharp demarcations between
affected and unaffected tissue (O, dashed line, arrows).
Evidence of axonal stress was also detected (arrowheads).
Scale bars, (A)–(D) 1.5 mm; (E)–(K) 100 mm; (L)–(O) 2 mm.
The observations presented in this study hold
important implications for understanding the
possible long-term safety of AAV gene therapy
for KD and emphasize the need for continuous
monitoring and improvement of therapeutic
protocols and strategies for KD and other genetic
leukodystrophies.
RESULTS
Late-onset multifocal demyelination in the
brain of AAV9-GALC-treated TWI mice
TWI (GALC-deficient) mice were treated with a
global AAV9-GALC gene therapy regimen (i.c.,
i.v., and i.t.) after birth, as previously described.7
The AAV9-GALC therapy was compared along-
side an analog (bone marrow transplantation,
BMT)9,11,14,15 of the current best clinical practice
(hematopoietic stem cell transplantation,
HSCT),16–18 both alone and in combination
with one another.
The TWI mouse displays diffuse demyelination throughout the CNS
(Figures 1B and 1F) and peripheral nervous system (PNS) (Figures
S1A and S1B), confirmed histologically in sham-treated TWI mice
(sham TWI). AAV9-GALC gene therapy, globally administered in
a high-dose regimen forestalled this demyelination at P40 both alone
(TWI+AAV) (Figure 1G) or in combination with BMT
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(TWI+AAV+BMT) (Figure 1H) to levels indistinguishable from a
wild-type (WT) P40 animal (Figure 1E). The PNS was equally pro-
tected at the P40 time point (Figures S1E and S1F) by AAV9-
GALC to levels compatible with WT (Figures S1C and S1D).
As reported by Marshall et al.,7 brain tissue from aged (180 days or
older) TWI+AAV (Figure 1C) and TWI+AAV+BMT (Figure 1D)
showed a global well-preserved myelination comparable to WT
brains (Figure 1A), underscoring the power of GALC correction
following neonatal gene therapy. A closer inspection of aged, treated
TWI brains revealed the presence of multiple (ranging 2–8 lesions per
brain), distinct regions of focal demyelination (0.5–2 mm3) (Figures
1C and 1D, arrows and arrowheads). Within the lesions, there was
a complete loss of myelin, confirmed by both myelin basic protein
(MBP) staining (Figures 1J and 1K, arrows and arrowheads) and by
electron microscopy (EM) (Figure 1O). EM identified the ultrastruc-
ture of these lesions, highlighting the stark delineation between
healthy and demyelinated tissue (Figure 1O, dotted line and arrows).
Within the demyelinated lesions, damaged tissue in aged TWI+AAV
animals (Figure 1O) had a similar structure to the diffuse damage seen
in sham P40 TWI (Figure 1M). Axons with thinmyelin layers, sugges-
tive of a remyelination process,19 were not found in the lesions, indi-
cating that these lesions progressively worsened without evidence of
remission or effective myelin repair. Areas adjacent to the lesions
(Figures 1C, 1D, 1J, 1K, and 1O) remained relatively intact and
normal appearing, comparable to aged WT (Figures 1A, 1I, and 1L)
and the P40 TWI+AAV (Figures 1G, 1H, and 1N); however, there
was some evidence of axonal stress (e.g., axonal swelling) in axons
adjacent to lesions (Figure 1O, arrowheads).
Not all regions of the brain were affected equally. Myelinated tracts of
the stria terminalis (Figures 1C, 1D, 1J, and 1K, arrows) were affected
in all animals. Other affected regions included cerebellar and brain-
stem white matter (Figures 1C and 1D, arrowheads) and corpus cal-
losum (Figure 1J, arrowheads). Lesions were identified in the brains of
all AAV9-GALC-treated animals examined (6 total examined: 3
TWI+AAV, 3 TWI+AAV+BMT). Plaques were not present in any
of the brains of treated TWI evaluated at earlier ages (P40; n = 5).
Within the CNS, this localized demyelination was present only in
the brain. Serial sections from spinal cords from both TWI+AAV
and TWI+AAV+BMT animals were examined and showed no evi-
dence of focal demyelination (Figure S2). In addition, focal demyelin-
ation was not observed within the PNS of aged TWI+AAV (Figures
S1G and S1H) or TWI+AAV+BMT animals (data not shown).
In our previous paper,7 we showed that AAV alone or in combination
with BMT ameliorated signs of disease for the first 6–8 months of life
through our clinical disease scoring system. The clinical disease score
is composed of three components: mass change (which was shown in
our previous report7), presence of tremor, and locomotor ability. To
better understand when pathology and signs of disease begin, loco-
motor ability and tremor in relation to age were quantified over
time (Figures S3A and S3B). This showed that tremor begins in
most TWI+AAV and TWI+AAV+BMT animals at 16 weeks of
age and locomotor ability begins to decline at 20 weeks of age.
This suggests that although these animals display an overall pro-
nounced and lasting clinical improvement and increased survival,
there are clinical deteriorations that can be appreciated during these
animals’ aging.
Multiple studies have used an AAV gene therapy to treat TWI mice,
but only two reports11,14 have presented some imaged evidence of
analogous myelin lesions in the CNS of AAV-treated TWI mice. It
is important to note the differences in gene therapy design, methodol-
ogy, and time of analysis between these two studies and ours. Haw-
kins-Salsbury et al.14 used a combination of L-cycloserine, BMT, and
AAV2/5-GALC. Mice received gene therapy (i.c., 6  109 vector ge-
nomes [vg]/mouse and i.t., 1.5  1010 vg/mouse) between post-natal
days (P)2 and 3, followed by BMT on P4 and L-cycloserine (an irre-
versible inhibitor 3-ketodehydrosphingosine synthase, ultimately
leading to decreased psychosine20) treatment starting at P5–7 for
the life of the animal. Histological analyses of myelin were done on
P160. In contrast, Karumuthil-Melethil et al.11 compared AAV9,
AAV001, and AAVrh10 administered i.t. (2  1011 vg/mouse) on
P11, with histological analyses performed at P35. Despite these meth-
odological differences, both studies presented some evidence of focal
lesions after an initial healthy period in treated TWI, but further anal-
ysis was not reported. To provide unbiased cross-examination of our
study, we examined an independent set of TWI mice produced by the
Sands lab and subjected to a triple combined treatment analogous to
that reported previously by that lab,14 with the relevant difference
that AAV2/5-GALC was replaced with the same AAV9-GALC vector
used in this present study (Figure S4). At P35, myelination in treated
TWI (Figure S4C) appeared indistinguishable fromWT (Figure S4A)
compared to untreated TWI (Figure S4B). However, multifocal de-
myelinated lesions were evident in the brain of aged, treated TWI.
Example images of demyelinating lesions in the corpus callosum are
shown at P160 (Figure S4D, arrows) and terminal P500 (Figures S4E
and S4F, arrows). These findings from an independent study indicate
that these multi-focal lesions are not protocol dependent and are a po-
tential comorbidity of AAV gene therapy in different contexts.
Reduced expression of therapeutic GALC enzyme and
accumulation of psychosine in focal demyelinated lesions
To understand the cause(s) of these lesions, we aimed to determine
whether the expression of therapeutic GALC was compromised in
lesioned areas. Fluorescent in situ hybridization (FISH) using a ribop-
robe specifically designed to recognize the mouse Galc mRNA
confirmed the robust expression of therapeutic Galc mRNA
throughout the brain of P40 TWI+AAV+BMT (Figures 2B and
2G), but a total absence of Galc mRNA in the sham TWI brain (Fig-
ures 2A and 2F). Expression in P40-treated TWI is close to that
observed in WT brains (Figures 2D and 2I). In contrast, ISH in
lesioned areas (e.g., corpus callosum, brainstem) of aged AAV-treated
TWI brains revealed regions with significant reductions of Galc
mRNA expression (Figures 2C and 2H, dotted lines). Specificity
and background binding levels of the probes are displayed as well
(Figures 2E and 2J).
www.moleculartherapy.org
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The localized decline of Galc mRNA was accompanied by analogous
decreases in the levels of GALC protein immunodetected within le-
sions of aged, treated TWI brains. This staining shows the absence
of GALC immunoreaction within a lesion of an aged TWI+AAV (Fig-
ure 2L, inside dotted lines). The lesion was identified by its lack of im-
munoreaction to anti-MBP antibodies (Figure 2M). The lesions were
noted to be hypercellular via DAPI staining (Figure 2N). GALC pro-
tein was immunodetected in non-lesioned areas of aged, treated TWI
brains (Figure 2L, outside dotted lines), P40-treated TWI brains (Fig-
ure 2K), and aged WT brains (Figures 2P–2R), but not in sham TWI
(Figure 2O). These results provide evidence that demyelinating
lesions are associated with areas in the TWI brain where GALC
expression was initially restored by AAV9-GALC therapy, but subse-
quently declined during aging.
To have a measure of the functional effect of this localized decline of
expression of therapeutic GALC, serial sections of treated TWI brains
were subjected to micropunches and liquid chromatography-tandem
mass spectrometry (LC-MS/MS) for the detection of psychosine levels.
Figure 2S shows that, albeit not reaching statistical significance, lesioned
areas of the aged TWI+AAV brain contained detectable levels of psy-
chosine that were elevated as compared to younger P40 TWI+AAV.
Figure 2. Focal loss of GALC expression within demyelinating lesions
(A, B, D, F, G, and I) In situ hybridization using antisense probes recognizing GALC demonstrates the lack of expression ofGALCmRNAwithin the brains of the shamP40 TWI
(A and F), while P40 TWI+AAV+BMT (B and G) and aged WT (D and I) mice showed robust GALC expression in 2 regions that were common for lesions to occur: the corpus
callosum and the brainstem. (C, E, H, and J) Aged TWI+AAV animals were found to have a significant reduction inGALC expression in lesion sites in these 2 regions (C and H,
dotted line). Background binding levels of sense probes (J) and its specificity (E) are displayed as well. (K–R) Immunohistochemical staining for MBP (green) andGALC (purple)
showed show limited MBP and GALC staining in sham TWI brain (O) in comparison to P40 TWI+AAV (K) and WT (P–R) mice. Minimal GALC (L) and MBP staining (M) was
detected within lesions in aged TWI+AAV mice (L–N, dotted line). (S) Psychosine levels measured from micropunches within the lesion areas from P40 and aged TWI+AAV
and normalized to levels in WT (n = 3 per group). Scale bars: 100 mm.
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These analyses provide evidence that localized deficits of GALC activity
developed in defined regions of the treated adult TWI brain.
Reduction of GALC expression associated with relapse of
lysosomal responses in focal demyelinated lesions
In naive TWI brains, the lack of GALC expression is always accom-
panied by abnormal lysosomal responses,7 including exacerbated
expression of lysosomal proteins such as LAMP1 and the presence
of abundant lysosomal structures throughout the brain (Figure 3B).
Aberrant lysosomal responses were detected in multiple brain cell
types, including oligodendrocytes (Figures 3E–3I), neurons (Figures
3J–3N), and microglia (Figures 3O–3S). WT brains (Figures 3A, 3E,
3J, and 3O) do not display these abnormal lysosomal responses.
Immunofluorescent staining for LAMP1 revealed a multifaceted
pathology within the focal demyelinated areas of the aged AAV9-
GALC-treated TWI (Figures 3C and 3D). Compared with WT (Fig-
ures 3A, 3E, 3J, and 3O) and sham TWI (Figures 3B, 3E, 3J, and
3O), gene therapy successfully corrected lysosomal responses in oli-
godendrocytes, neurons, and microglia throughout the brain of
TWI+AAV animals at P40 (Figures 3G, 3L, and 3Q). In stark
contrast, brain tissue from aged TWI+AAV and TWI+AAV+BMT
had abundant LAMP1+ material accumulated, indicating a return
to a pathological state in oligodendrocytes (Figures 3H and 3I), neu-
rons (Figures 3M and 3N), and microglia (Figures 3R and 3S). Quan-
tification (Figure 3T) of LAMP1 expression confirmed that the robust
correction of LAMP1 observed at P40 weakened in aged, treated TWI.
These results indicate the resurgence of lysosomal dysfunction in
focal brain areas during the aging of treated TWI.
Adult-onset lesions are robustly microgliotic and exhibit
fibrinogen extravasation
Remyelination is known to occur within TWI, as normal repair mech-
anisms attempt to replace damaged myelin.21 This includes the
recruitment of inflammatory cells such as microglia,21 which was
observed to occur in these lesions, creating glial scarring around the
lesion margins (Figure 4C, arrows) in comparison to WT (Figure 4B)
and shamTWI (Figure 4A) brains. Localizeddamage towhitematter is
usually associated with leakage of the blood-brain barrier (BBB).22–26
In fact, extravasation of plasma proteins, particularly fibrinogen into
the brain, has been reported to act as a mediator of microglial activa-
tion and damage in multiple neurological conditions,27,28 including
disorders with multi-focal demyelination such as multiple sclerosis.29
Plasma protein leakage was initially assessed with an antibody-recog-
nizing fibrinogen, revealing extensive fibrinogen involvement within
lesions of aged TWI+AAV (Figure 4F, arrow). Sites of fibrinogen
extravasation were populated by activated IBA1+microglia and highly
restricted to demyelinated lesion areas (Figures 4G–4I, arrow). Fibrin-
ogen leakagewas not observed in shamTWI orWTaged animals (Fig-
ures 4D and 4E). Leakage of plasma proteins was not observed in the
spinal cord (Figure S5), which was consistent with an absence of le-
sions (Figure S2).
Activation of the fibrinogen-SMAD pathway facilitates a potent
inflammatory glial response in adult-onset lesions
Extravasation of fibrinogen is a common finding in the lesioned brain
regions of patients with multiple sclerosis and ischemic injury, and
this extravasated fibrinogen is associated with astrogliosis.22–27,30
Recent findings have shown that extravasated fibrinogen promotes
shifting neural progenitors’ fate to astrocytes by activation of the
bone morphogenic protein (BMP) pathway.31 We assessed the
involvement of these responses in the neuropathology observed in
the brain of aged, treated TWI mice. We used immunohistochemistry
to examine the association between fibrinogen in demyelinating le-
sions with glial fibrillary acidic protein (GFAP). We detected a strong
gliotic response with abundant GFAP+ astrocytes (Figure 5A) engulf-
ing lesioned areas containing immunodetectable fibrinogen (Figures
5B and 5C). This gliotic response was in stark contrast to areas devoid
of demyelinated lesions in the aged brains of TWI+AAV, which
lacked any detectable fibrinogen and GFAP astrogliosis, such as the
striatum (Figures 5D–5F), and to the generalized gliosis observed
throughout the brains of the sham TWI (Figures 5G–5I). We did
not find significant differences in astrocyte responses between P40
TWI+AAV (Figure 5J) and adultWT (Figure 5K), strongly suggesting
that astrogliosis and fibrinogen extravasation in lesions developed
together during aging of the treated TWI. Secondary antibody con-
trols are shown in Figure 5L. Quantification of these responses
showed significant increases in GFAP in aged TWI+AAV brains (Fig-
ure 5X) and of the alpha unit of fibrinogen (Figure 5V). Inflammatory
astrogliosis in aged, treated TWI was further confirmed by the quan-
tification of the levels of Serpina3 and LCN2, two known proteins
involved in the activation of astrogliosis in multiple sclerosis,32,33
revealing significant upregulations (Figures 5Y and 5Z) in the aged,
treated TWI brains. These results confirm the activation of a strong
inflammatory response in these mice.
Immunohistochemistry for SMAD1 showed strong reactivity within
the demyelinated lesions of the aged AAV-treated TWI brain (Figures
5M–5O). As expected, SMAD1 reactivity was strongly associated with
gliotic GFAP+ detection (Figures 5P–5R) and fibrinogen (Figures 5S–
5U). Phosphorylation of SMAD1 at Ser 463/465 is a readout of the
Figure 3. Lysosomal abnormalities relapse in aged, treated TWI
Staining for the lysosomal marker LAMP1 was used as a readout of lysosomal stress. (A–D) LAMP1 staining of sagittal brain slices depicts robust lysosomal accumulations
(arrows) associated with the lesions of aged TWI+AAV (C) and TWI+AAV+BMT (D) in contrast to widespread lysosomal accumulation within sham P40 TWI (B) and control
levels in P40 WT (A). (E–S) Tissue was double-stained for LAMP1 as well as cell-specific markers APC (E–I, oligodendrocytes), NeuN (J–N, neurons), and IBA1 (O–S, mi-
croglia). LAMP1 accumulation (arrows) was observed in oligodendrocytes, neurons, and microglia of sham P40 TWI (F, K, and P), while it was minimal in WT tissue (E, J, and
O). Lysosomal accumulations were not evident in P40 TWI+AAV (G, L, and Q) but were seen in oligodendrocytes, neurons, and microglia located within the lesions of aged
TWI+AAV (H, M, and R) or TWI+AAV+BMT (I, N, and S). In addition, quantitative western blots of LAMP1 expression (T) confirmed increased LAMP1 levels in aged, treated
TWI brains (n = 4–6; *p < 0.05). Scale bars: (A–D) 1.5 mm; (E–S) 30 mm.
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activation of SMAD. Phospho-SMAD1 (pSMAD1) was significantly
increased in the aged TWI+AAV brain (Figure 5W), in support of
the involvement of this pathway.
Degradation of tight-junction components underlying the
leakage of fibrinogen in adult-onset lesions
There is a direct correlation between the quantity of plasma proteins
and other blood elements leaking in the brain parenchyma and the
integrity and permeability of the BBB.23 The efficiency of the BBB
to prevent extravasation is largely regulated by the presence of tight
junctions, which serve to fully seal the space between endothelial cells
of the brain vasculature.25,29 To evaluate the possibility that fibrin-
ogen extravasation is associated with BBB discontinuity, we examined
the integrity of the BBB with isolectin-fluorescein isothiocyanate
(FITC) staining, which reliably detects disruptions in the continuity
of the BBB (Figures 6A–6F). Our results clearly show that within
the lesioned areas of the aged, treated TWI, the vessel walls have dis-
continuities (Figures 6E and 6F, arrowheads). In contrast, non-
lesioned areas of the aged, treated TWI brains (Figure 6D, arrows)
and P40 TWI+AAV (Figure 6C, arrows) showed a smooth and
continuous staining, indistinguishable from WT vessels (Figure 6B)
and sham TWI (Figure 6A). Several protein components of the tight
junction are sensitive to instability and degradation. Occludin and
various claudin proteins play key scaffolding roles in tightening the
BBB and can be targeted for degradation by matrix metalloprotei-
nases such as MMP9.34,35 To analyze whether the discontinuity of
the vessel detected by isolectin labeling was accompanied by changes
in tight junction components, we measured the levels of occludin,
claudin5, and activated MMP9. A significant increase in the active
form of MMP9 in protein lysates of aged TWI+AAV mice was iden-
tified (Figure 6G). A stark increase in the presence of the 60-kDa
degraded form of occludin was readily observed in aged TWI lysates,
statistically significant from degradation levels observed in any other
conditions (Figure 6H). Similarly, levels of claudin5 were significantly
reduced in aged TWI+AAV brains with respect to the levels in any of
the other experimental conditions (Figure 6I).
Figure 4. Lesions display evidence of microgliosis and plasma protein extravasation
(A–C) Tissue was stained with IBA1 to examinemicroglia, which revealed extensivemicrogliosis in the lesioned areas (C, arrows) in contrast to extensive, global microgliosis in
sham TWI (A) and minimal microglia in aged WT (B). (D–F) Tissues were double stained for fibrinogen and IBA1, which showed that fibrinogen leakage was limited to the
lesioned regions in aged TWI+AAV (F) and colocalized with IBA1 staining. No fibrinogen leakage was observed in sham TWI (D) or aged WT (E). (G–I) Aged TWI+AAV were
double stained for fibrinogen (G) andMBP (H) to depict how fibrinogen extravasation is present in the lesioned areas (I). Scale bars: (A–C)1.8 mm; (D–F)1.3 mm; (G–I) 100 mm.
www.moleculartherapy.org
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Lesion-associated OPCs are depleted of detectable GALC:
reemergence of GALCmetabolic deficiency by exhaustion of the
therapeutic AAV genome
Because oligodendrocytes are the main contributor to psychosine
production in KD,36 the recruitment of proliferating OPCs37,38 lack-
ing the therapeutic transgene to an area for damage (likely a doomed
attempt to improve remyelination) could contribute to further psy-
chosine accumulation, leading to additional damage. Based on these
findings, we hypothesized that the proliferation of OPCs in the
treated TWI brain dilutes the episomal AAV9-GALC plasmid,39–43
rendering de novo OPCs with minimal to zero therapeutic GALC
enzyme. Accordingly, these newly formed cells are expected to
have limited, if any, lysosomal GALC activity to metabolize psycho-
sine.42 Upon transducing a cell, the DNA packaged within an AAV
primarily forms extra-chromosomal, non-replicating episomes.39–43
We hypothesized that the focal lesions occurred because of a local-
ized loss of AAV9-GALC DNA leading to the loss of GALC and
the resulting accumulation of psychosine. Multiple lines of
Figure 5. Areas with fibrinogen deposition present widespread astrogliosis
(A–C) Tissue sections double stained for fibrinogen (green) and GFAP (purple) showed strong colocalization of these proteins within the lesioned areas of aged TWI+AAV. (D–
F, J, and K) In contrast, non-lesioned regions of aged TWI+AAC such as the striatum (D–F), P40 TWI+AAV (J), and aged WT (K) had undetectable fibrinogen and normalized
expression of GFAP+ astrocytes. (G–I) Sham P40 TWI showed no fibrinogen but extensive astrogliosis through the brain. (L) Background staining of secondary antibodies is
shown. (M–O) Aged TWI+AAV tissue was double stained for MBP (M) and SMAD1 (N) revealing that SMAD1 expression was limited to the demyelinated lesions (O). (P–R)
Likewise, robust expression of SMAD1 (Q) was associated with GFAP (P) in aged TWI+AAV tissue (R). (S–U) Tissue was double stained for fibrinogen (S) (green) and SMAD1
(T) (purple), again showing a strong colocalization within the lesions (U). (V–Z) Quantitative immunoblotting enabled the quantification of increased levels of fibrinogen—alpha
subunit, (V), phosphorylated SMAD1 (W), GFAP (X), Serpina3 (Y), and LCN2 (Z). n = 3; *p % 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001. Scale bars: 100 mm.
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experimental evidence support this. We examined the expression of
GALC protein in OPCs. Figure 7 shows that platelet-derived growth
factor receptor-a+ (PDGFR-a+) OPCs (Figure 7B, arrows) found in
lesioned areas of aged TWI+AAV are completely devoid of detect-
able levels of GALC (Figures 7A and 7C, arrows), similar to
PDGFR-a+ OPCs in sham TWI (Figures 7G–7I, arrows). Similar
findings were observed in aged TWI+AAV+BMT (data not shown).
Instead, PDGFRa+ OPCs located in unaffected regions of the TWI
brain such as cortex (Figure 7E, arrow) contained detectable levels
of GALC (Figures 7D and 7F, arrow), similar to PDGFR-a+ OPCs
in WT (Figures 7J–7L, arrows).
Demyelinating lesions contain dividing oligodendrocyte
progenitors
DAPI staining (Figures 8B–8E) revealed a hypercellular profile
within lesions in comparison to WT (Figure 8A). Given the hyper-
cellularity of these lesions, we examined these regions for the pres-
ence of dividing cells. For this, we used immunofluorescent
Figure 6. Degradation of endothelial tight junctions in blood vessels within lesions
(A–F) Tissue was stained with isolectin-FITC to examine the integrity of capillaries. (E–D) This showed that capillaries within aged TWI+AAV lesions (E and F) were damaged
and disrupted in contrast to the non-lesioned areas such as the cortex (D). (A–C) The continuous staining observed in capillaries in sham P40 TWI (A), P40 WT (B), and P40
TWI+AAV (C) underscores the lack of vasculature disruption. (G–I) Immunoblotting enabled the quantification of changes in increased MMP9 (G), degradation of occludin (H),
and reduction of claudin5 (I). n = 3; **p % 0.01, ****p % 0.0001. Scale bars: 75 mm (A–F).
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Figure 7. Loss of GALC transgenic expression in OPCs within lesions
Tissue was double-stained for GALC (purple) and PDGFR-a (green) to investigate the possibility of OPCs losing the GALC transgene in aged, treated TWI brains. (A–F)
Confocal microscopy showed that OPCs within lesions of aged TWI+AAV (A–C, arrows) lacked detectable levels of GALC protein, while OPCs located outside lesioned areas
such as the cortex (D–F, arrow) showed GALC expression. (J–L) Aged WT showed detectable GALC expression within OPCs (J–L, arrows), while sham P40 TWI showed a
total absence of GALC expression within OPCs (G–I, arrows). Scale bars: 30 mm.
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identification of proliferative cell nuclear antigen (PCNA)-positive
nuclei. Abundant PCNA+ nuclei were primarily concentrated
around the margin and within the lesions, suggesting the lesions
were active zones of cellular proliferation (Figures 8B–8E). Prolifer-
ation of OPCs has been shown to occur in the brain of TWI mice,44
especially during the late stages of disease, as well as in the adult hu-
man brain.45–47 To determine whether dividing OPCs made up a
significant portion of the proliferative cells found in lesions, we
co-stained brain sections with antibodies against PCNA and
PDGFR-a, a well-characterized receptor expressed by replicating
OPCs.48 Our results confirmed the presence of abundant double-
positive PDGFR-a/PCNA OPCs undergoing cell division within le-
sions (Figures 8B–8E, arrows). Secondary antibody controls are
shown in Figure 8F. To quantify this response, we performed quan-
titative PCR (qPCR) for the Pdgfra mRNA. Figure 8M shows that
while P40 TWI+AAV mice have levels of PdgframRNA comparable
to WT, the brain of aged TWI+AAV mice have an 2-fold increase
in Pdgfra mRNA expression. Western blot analysis shows similar
changes in the levels of PDGFR-a protein (Figure 8N). Finally,
counting of the PDGFR-a+ OPCs within the lesion areas (Figures
8G–8L) also showed increased levels of OPCs (Figure 8O) in the
aged TWI+AAV brain in comparison to P40 TWI+AAV.
We tested our hypothesis by transducing TWI neuroglial progeni-
tors with AAV9-GALC at a multiplicity of infection (MOI) of
5,000, which approximates the dosage used in our in vivo gene ther-
apy of TWI mice.7 Samples were taken every 4 days for the quanti-
fication of episomal DNA via qPCR, GALC activity using our
fluorescent assay,7 and psychosine using MS. The results revealed
a decline in viral DNA over time (Figure 9A). GALC activity per
cell rapidly declined as well, showing a statistically significant
decrease in 4 days, and it was no longer statistically different from
the untreated TWI control after 20 days (Figure 9C). The decrease
in viral DNA and GALC activity was not due to cell death, as the
cumulative cell count over time showed a rapid increase in cells
(Figure 9B).
To assess whether the loss of GALC activity led to an increase in psy-
chosine in TWI cells, we quantified psychosine by LC-MS/MS7 and
compared the levels between early (4–8 days post-infection, DPI)
and late (16–20 DPI) time points. Our results show that a significant
decrease in psychosine in AAV-treated cells is measurable at early
time points (4–8 DPI). In contrast, psychosine levels in AAV-treated
cells increased to levels statistically indistinguishable from untreated
cells at later time points (16–20 DPI) (Figure 9D). These results sup-
port our hypothesis that non-replicating, episomal AAV DNA is
gradually diluted as cells replicate, leading to the reemergence of psy-
chosine accumulation in newly generated TWI cells.
Finally, we investigated whether a similar dilutional process occurred
in the mouse brain, particularly during proliferation of OPCs. This
was accomplished by transducing WT mice with AAV-001-GFP,
which was engineered to preferentially target OPCs and oligodendro-
cytes.49 Mice were analyzed for GFP fluorescence at 7, 30, and 60 days
of age (Figure 9E). This revealed a statistically significant decline in
GFP fluorescence over time from an average fluorescence of43 fluo-
rescent units (FUs) at P7 to14 FUs at P60 (Figure 9E). The number
of fluorescent cells was also quantified, which revealed no significant
difference between all time points (Figure 9F). These results further
support our hypothesis that the proliferation of progenitor cells in
the brains of adult AAV9-GALC-treated TWI (Figure 4) facilitates
the dilution of therapeutic AAV-GALC genomes (Figures 2 and 9)
and leads to a progressive decrease in corrective levels of GALC activ-
ity with an increase in psychosine (Figures 2 and 9) and recapitulation
of neuropathology in localized areas (Figure 1).
In summary, our study presents multipronged experimental evidence
that adult-onset multifocal demyelinating inflammatory lesions
linked to BBB disruption and extravasation of plasma fibrinogen
form in the brains of neonatally AAV9-GALC- and AAV9-GALC+-
BMT-treated TWImice. Our study identifies the focal reemergence of
GALC metabolic deficiency in treated TWI arising from the prolifer-
ation of OPCs leading to the loss of the episomal AAV DNA contain-
ing the therapeutic transgene.
DISCUSSION
AAV gene therapy is proving to be a viable and useful treatment
option for monogenetic disorders such as KD. The efficacy of AAV
vectors seems paramount if administrated in early infancy, lasting sig-
nificant periods of time thereafter. Our published protocol7 is an
example of early intervention leading to an effective means of signif-
icantly extending the lifespan and delaying the onset of demyelination
and inflammation, matching the efficacy of AAV therapies observed
by other groups.8,11–14,50 However, the dynamics of maintaining ther-
apeutic levels of GALC correction during longer periods of time ex-
tending into adulthood are less clear. Here, we are the first to describe
in detail an adult-onset presentation of KD pathology in long-surviv-
ing AAV-treated TWI mice as multi-focal demyelinating lesions with
associated inflammatory cells and lysosomal dysfunction. These data
are supported by the discovery of similar lesions in aged mice from an
independent study performed by the Sands group.14 Our work shows
that these lesions are observed only in long-lived animals. Although
many of the animals in this study surpassed survival benchmarks of
some previous reports, it does not seem that longevity is a significant
factor, as these lesions were identified as early as P180. The reason
may also be secondary to the unique regimen of the protocol used,
which included a global delivery (via i.c., i.t., and i.v. injections) of
Figure 8. Lesions display signs of active cellular replication with increased numbers of OPCs
(A–F) DAPI staining revealed hyper-cellularity in lesions in AAV9-GALC-treated TWI mice (B–E, dotted line) compared to WT (A), containing abundant proliferating PNCA+,
PDGFR-a+ OPCs (D, arrows). Secondary antibody controls are shown in (F). (G–L andO) Tissue from shamP40 TWI (G), P40 TWI+AAV (H), agedWT (I), aged TWI+AAV (J and
L), and aged TWI+AAV+BMT (K) were stained with antibodies against PDFGr-a to enable the counting of OPCs (displayed in O). (M) Quantitative PCR of PDGFR-amRNA. (N)
Western blot quantification of PDGFR-a protein. n = 3; *p < 0.05, **p < 0.01. Scale bars: 100 mm (A, B, and G–L); 75 mm (C); 30 mm (D–F).
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a higher titer AAV-GALC therapy regimen.7,8,11,14 The widespread,
high titer treatment could have resulted in greater initial correction,
which may have hidden the local loss of GALC leading to the
observed focal lesions.
Regional distribution of lesions in the brain does not appear to repre-
sent a limitation in the initial distribution of the vector aswe confirmed
GALC expression at P40 within the regions later affected by local
demyelination. This idea is further supported by previous data that
confirmed the AAV9-GFP vector to be present in all areas of the brain,
and that there was no localized demyelination or neuroinflammatory
phenotype observed in AAV9-GALC-treated animals at P40.7 The
mechanism responsible for initiating damage in these lesions, and
Figure 9. AAV DNA and transgene expression diminish
in vitro and in vivo over time
(A–D) In vitro. (A–C) AAV-DNA (A) and GALC activity (C) per
cell decreases over time in a manner inversely proportional to
cumulative cell count (B). (D) LC-MS/MS quantification of
psychosine shows that at early time points, 4–8 days post-
infection (DPI), there was a significant reduction of psychosine
after treatment with AAV9-GALC. Late time points, 16–20
DPI, show that there is no longer a significant difference be-
tween AAV9-GALC treated and untreated cells. (E and F)
In vivo quantification of fluorescence intensity (E) of trans-
duced cells in the brains of WT mice after transduction with
AAV-001-GFP at 7, 30, and 60 days after injection. There is a
significant decrease over time in AAV-001-GFP-mediated
GFP fluorescence in mice brains. Counting the number of
GFP+ cells (F) revealed that the total number of transduced
cells remains relatively constant. n = 3 for (A)–(D); n = 4 per
time point for (E) and (F). The asterisk indicates the difference
between groups and the # indicates the difference between
time points. *p % 0.05, **p % 0.01, ****p % 0.0001.
therefore driving the regional specificity, could be
related to local rates of myelin turnover, involving
the generation of new oligodendrocytes. In fact,
the proliferation of OPCs has been shown to occur
in the TWI CNS44 as well as in the adult human
brain.45–47Myelination is a key driver of psychosine
production,51 suggesting that these regions may
normally undergo increased myelin remodeling,
with uncorrected OPCs acting as a potential trigger
for damage as animals age. Other studies have pre-
sented evidence of regional differences in myelin
quality,52 which may be related to adult myelin re-
modeling following normal motor learning.53 One
anatomical region consistently affected by focal
demyelination was the stria terminalis, directly
adjacent to the subventricular zone, an area of per-
manent cell proliferation in the adult brain.54
This concentrated insult seems to reveal localized
areas of myelin vulnerability and blood-brain/
blood-cerebrospinal fluid barrier vulnerability,
characterized by serum extravasation and fibrinogen leakage, which
has been demonstrated to further activate microglia recruitment and
axonal damage via a CD11b/CD18 mechanism.27 The observation
of plasma protein extravasation implies that there are deficits at the
BBB (capillaries), the post-capillary venules, or the blood-cerebrospi-
nal fluid barrier. Although the infiltration of hematogenous cells into
the CNS of TWI has been reported,55 leakage of plasma proteins has
not been observed previously. In fact, the BBB had been shown to
remain largely intact in the TWI,56 suggesting the emergence of a
new mechanism of damage in aged AAV9-GALC-treated TWI.
Because the AAV vector DNA exists largely as non-replicating extra-
chromosomal episomes, cellular proliferation inexorably causes its
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progressive dilution by successive cell division, which decreases the
average number of episomes per cell. The in vitro experiments
demonstrated this by showing that episomal viral DNA and transgene
encoded GALC declined over time, inversely proportional to cumula-
tive cell count. This effect correlated to increases in psychosine levels,
proportionally to cumulative cell count. The in vivo experiments pro-
vided further evidence of this effect by showing that fluorescent levels
originating from AAV-encoded GFP decreased over time, despite the
maintenance of the overall number of fluorescent cells over the dura-
tion of the experiment. Because fluorescence is proportional to the
transgene expression levels, as transduced cells divide and dilute
AAV genome, highly fluorescent cells become less fluorescent, to
the point at which fluorescence is minimal or indistinguishable
from background.
Given enough time, some cells may lose all copies of the therapeutic
episomal GalcDNA, essentially reverting to an untreated state. Those
cells and all progeny cells thereafter will be metabolically deficient in
their ability to catabolize psychosine. The rapid loss of AAVDNA and
GALC transgene per cell in transduced TWI neuroglial progenitors as
well as the decline of AAV-mediated GFP fluorescence over time sup-
port this episome dilutional hypothesis. We speculate that this dilu-
tional effect could explain the reduction of GALC activity and
increased psychosine concentrations detected in TWI as the animals
age, compared to levels observed at P40, as previously reported.7 In
the context of myelin remodeling, if newly generated TWI OPCs
continue to increase the local levels of psychosine, this may activate
repair mechanisms that direct newly formed cells to the site of
injury.21 Uncorrected repair/inflammatory cells (e.g., OPCs, astroglia,
microglia), possessing a limited capacity to break down psychosine,
likely enhance the local lesion into a demyelinated lesion. This is sup-
ported by the observed loss of Galc transcriptional expression and
GALC protein within the lesions and, more important, in OPCs
within the lesion, suggesting a cellular turnover with the invasion of
non-corrected cell types.
Beyond an evaluation of the ability of an AAV vector to initially cor-
rect the pathophysiology of disease, our results provide an interesting
observation for how a localized loss of lysosomal function can lead to
a presentation that is reminiscent of other focal demyelination such as
multiple sclerosis. Heterozygous Galc mutants have been shown to
have reduced remyelination and clearance of myelin debris,57,58
which supports our theory that the progressive loss of GALC in-
creases myelin vulnerability in the adult and aging brain.
Our study has not fully addressed the temporal nature of how the le-
sions develop. At this time, we hypothesize that glial cells within the
lesioned areas may naturally replicate faster than other regions of
the CNS in response tomyelin remodeling, leading tomore rapid dilu-
tion of the therapeutic episomal transgene. This would explainwhy the
lesions were only found within specific areas. Initially, these cells may
be metabolically functional, aided by cross-correction from neigh-
boring cells secreting GALC.59–61 However, uncorrected cells, as
well as an exponentially increasing number of initially corrected cells
losingAAVepisomal copies, reach a point atwhich psychosine burden
from the uncorrected cells is too large for neighboring cells to correct
and pathological effects emerge.3,62–69 Cell death and debris result in
astrogliosis, inflammation, and activation of microglia. Inflammatory
cells are known to produce MMP9,70–72 which participates in break-
down components of the BBB such as claudin5.34,35 BBB failure allows
the extravasation of blood components such as fibrinogen, which aug-
ments astrogliosis, inflammation, and generalized damage.
We did not observe signs of remyelination within the lesions on EM
microscopy; however, this still leaves the question of whether these le-
sions progressively worsen or whether there may be periods of remis-
sion. Progressive lesions would be consistent with the proposed
mechanism of episomal dilution and recruitment of uncorrected
repair cells, no longer containing GALC protein, and would lead to
a dysfunctional repair process. Further studies will address these as-
pects of the pathogenic mechanism.
The observations presented in this study hold important implications.
Undoubtedly, the recent cascade of positive results using AAV gene
therapy obtained in the KDmouse and GLD dog model7,10–12,14,73 ex-
emplifies the advantage of these vectors and supports their future use
in clinical trials for KD.While this excitement is totally justified and is
expected to gain further momentum, our study, along with recent
findings of liver toxicity in AAV-treated TWI mice,74 highlight the
importance of studying long-term safety when using AAV gene ther-
apy for CNS treatment. Further improvements in gene therapy re-
agents, delivery procedures, and quality control protocols will ensure
more refined, efficient, long-lasting, and safer results for KD patients.
MATERIALS AND METHODS
Animals and therapy protocol
Animal work in this study was performed in accordance with
approved protocols from the Animal Care and Use Committee at
the University of Illinois at Chicago. WT (Galc+/+) and TWI
(Galc/) mice were identified via PCR, as previously described,75
all maintained on a C57BL/6J background. Males and females were
both used in this study and randomly distributed as treatment was
initiated before the sex could be identified.
Neonatal TWI mice (P0–P1) were treated with AAV9-GALC via
three delivery routes—i.c., i.t., and i.v.— at a dosage of 9.0  109 vg
in 5  1 mL PBS, 8.25  1010 vg in 18 mL PBS, and 3.3  1011 vg in
30 mL PBS, respectively (4.2 1011 vg total, indicated as TWI+AAV).
i.t. injections were performed with a 28-G insulin syringe (4428-1,
Jelco/Smiths Medical ASD, Keene, NH, USA), inserted between L5
and S1, with 1% trypan blue added to the solution for tracing. i.v. in-
jections were delivered to the superficial temporal vein using a 28-G
insulin syringe. i.t. and i.v. injections were performed with pups back-
lit by a red-light lamp to visualize the spinal cord and vein. i.c. injec-
tions were performed as 5 separate injections (1 mL each, 2 in the left
cortical hemisphere, 2 in the right cortical hemisphere, and 1 in the
cerebellum) with a 26-G Hamilton syringe Model #701 (Hamilton,
Reno, NV, USA) inserted 1 mm into the brain parenchyma).
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Neonatal (P1)WT C57BL/6J were transduced with AAV-001-GFP or
PBS control at a dosage of 1.0 108 vg in 4 1 mL injections (bilateral
cortex and thalamus) with a 26-G Hamilton syringe.
All of the injections were performed under isoflurane anesthesia, 1 h
after a 2-mg/kg subcutaneous injection of meloxicam (Boehringer
Ingelheim Vetmedica, St. Joseph, MO) for the treatment of post-pro-
cedure pain and inflammation. Povidone-iodine cat. no. 67618-155
(Betadine, Stamford, CT, USA) was applied to the skin to disinfect
before injections.
After 24 h of recovery, a subset of AAV9-GALC treated mice (indi-
cated as TWI+AAV+BMT) were given an additional i.v. treatment
of bone marrow stem cells harvested from 6- to 8-week-old syngeneic
WT mice (30 million cells each treatment). Bone marrow cells were
harvested by flushing the tibiae and femur bones, pelleting the cells,
and then resuspending in Dulbecco’s modified Eagle’s medium cat.
no. 11966 (Thermo Fisher Scientific, Waltham, MA, USA). An addi-
tional control group of TWI mice was treated only with bone marrow
on P2 (TWI+BMT only). To measure BMT engraftment efficiency, a
subset of mice received bone marrow from C57BL/6J background
mice expressing ECFP fluorescent cells (mouse stock no. 004218,
The Jackson Laboratory, Bar Harbor, ME, USA). A group of sham
(sterile PBS) i.t., i.v., and i.c. injections on TWI andWTwere also per-
formed at P1–P2 days of age. After the treatments, the mice were re-
turned to their home cage with their mother.
Quantification of locomotor ability and tremor
Beginning on P20, animals had their locomotor capabilities and
tremor quantified twice per week until 20 weeks and once per week
thereafter.Quantificationwas performed by the sameblinded observer
every session. Locomotor ability was scored as follows: normal, 0;
waddling, 1; partial paralysis, 1.5; and full paralysis, 2. Tremor was
scored in a binary system of no tremor, 0 and tremor present,1.
Vector design and production
The AAV9-GALC vector was made using an inverted terminal repeat
(ITR) plasmid provided by Mark Sands’ laboratory at Washington
University in St. Louis, with the Chicken-Beta Actin (CBA-CAGGS)
promoter driving murine Galc, as described.50 The AAV9.47-GFP
vector was produced using a plasmid encoding EGFP, driven by the
CBh promoter,76 along with a SV40 poly A tail. These were packaged
as single-stranded genomes in an AAV capsid.
The AAV-001-GFP vector was made by the directed evolution of
AAV1, AAV2, AAV2i8, AAV2.5, AAV6, AAV8, AAV9, AAV9.47,
and AAVrh10 capsids. The capsid library was introduced to rats given
6-hydroxy-dopamine and then recovered via PCR. It contains an
enhanced GFP transgene under the hybrid CBh packaged with a
self-complementary genome,49 which was generously provided to
us by Dr. Stephen Gray.
Recombinant AAV vectors were generated by the triple transfection of
suspension HEK293 cells, using methods developed at the University
of North Carolina (UNC) Gene Therapy Center Vector Core facility
(Chapel Hill, NC).77 Vectors were dialyzed in phosphate-buffered sa-
line (PBS) containing 5% D-sorbitol and 350 mM NaCl.
Psychosine quantification
Fresh tissue was homogenized in H2O using a Vibra-cell ultrasonic
liquid processor model no. VCX 130 (Sonics and Materials, Newton,
CT, USA). Psychosine was extracted from tissue homogenates
(200 mg) via a methanol-acetic acid solution (0.5% acetic acid in
methanol). Using D-lactosyl-b1-10-D-erythro-sphingosine cat. no.
860542P (Avanti Polar Lipids, Alabaster, AL, USA) as an internal
standard, psychosine content was determined using MS/MS.
Chromatography
Separations were carried out using a Shimadzu (Kyoto, Japan) Nexera
ultra-high-performance liquid chromatography (UHPLC) system
equipped with a Waters (Milford, MA) Acquity UPLC BEH amide
column (2.1  50 mm, 1.7 mm) or an Agilent (Santa Clara, CA,
USA) 1290 Infinity II system equipped with a Poroshell 120 EC-
C18 UHPLC column (2.1 100 mm, 2.7 mm). Psychosine was eluted
from the ethylene bridged hybrid (BEH) amide column using a 30-s
isocratic flow of 85% acetonitrile and 15% 5 mM ammonium formate
and 0.2% formic acid in water at a flow rate of 0.90 mL/min. The in-
jection volume was 1 mL, and the column temperature was 45C. Data
acquisition and integration were carried out using Shimadzu Lab So-
lutions software. Psychosine was eluted from the Poroshell 120 EC-
C18 column using a gradient elution with mobile phases consisting
of solvent (A) water + 0.1% formic acid (B) acetonitrile + 0.1% formic
acid, and the flow rate was maintained at 0.3 mL/min. LC gradient
was as follows: 0–3.5 min held at 86% (B); 3.5–4 min (B) was
increased from 86% to 100%; 4–10 min held at 100% (B). Injection
volume is 15 mL, and the column was maintained at 40C.
Psychosine detection
The Agilent 1290 Infinity II UHPLC system was interfaced to an Agi-
lent 6550 quadrupole time-of-flight mass spectrometer equipped with
electrospray source, and the data were acquired in positive ion mode.
Source parameters were as follows: nitrogen gas temperature (200C),
drying gas flow (12 L/min), nebulizer (35 psi), sheath gas temperature
(350C), sheath gas flow (11 L/min), VCap (3,500 V), nozzle voltage
(500 V), and fragmentor voltage (130 V). MS and MS/MSm/z ranges
were set to 50–1,700 with fixed collision energies of 25 eV. MS and
MS/MS scan rates were 3 spectra per second. Data acquisition and
integration were carried out using Agilent MassHunter software. A
surrogate standard of D-lactosyl-b1-10-D-erythro-sphingosine was
used for relative quantification.
MS/MS
The Shimadzu Nexera UHPLC system was interfaced to a Shimadzu
LCMS-8050 triple quadrupole mass spectrometer equipped with pos-
itive ion electrospray and operated at unit resolution. Nitrogen was
used for nebulization at a flow rate of 3.0 L/min, drying gas at 10 L/
min, and heating gas flow at 10 L/min. The ion source capillary
and vaporizer temperatures were 300C. Psychosine was measured
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using collision-induced dissociation and selected reaction monitoring
(SRM). Argon was used as the collision gas at a pressure of 230 kPa.
The SRM transition for psychosine was m/z 462–282 and the transi-
tion for the surrogate standard D-lactosyl-b1-10-D-erythro-sphingo-
sine was m/z 624–282. The SRM dwell time was 50 ms.
GALC activity quantification
GALC activity was quantified as described previously.7 Lysate was
incubated with the GALC substrate cat. no. EH05989 (6HMU-b-D-
galactoside, Carbosynth, Berkshire, UK) at 37C for 17 h. Enzymatic
activity was quantified via fluorescence on a DTX 880Multimode De-
tector (Beckman Coulter, Brea, CA, USA) with 385 nm excitation and
450 nm emission.
ISH
FISH was performed on frozen brain sections with a GALC antisense
FITC-riboprobe prepared by in vitro reverse transcription using a
template derived from a 1.1-kb fragment of Galc. Briefly, the Galc
probe used for ISH was generated by sub-cloning a 1.1-kb BamHI/
XbaI piece of the 50 end of the murine GALC cDNA from pBRLsin-
PPT.hPGK mGALC-HA.Wrpe78 into the PGEM plasmid. Sections
were permeabilized by treatment with Proteinase K (1 mg/mL) for
20 min. After post-hybridization washes, bound FITC was detected
with a peroxidase-conjugated anti-FITC antibody (PerkinElmer,
Waltham, MA, USA) and incubation with the peroxidase substrate
FITC-tyramide.79 Following inactivation at 70C, MBP immunohis-
tochemistry was performed afterward, as previously described.7 Fluo-
rescence images were acquired using a Leica (Allendale, NJ, USA)
DM5500 TC confocal microscope.
Immunofluorescence
Mice were anesthetized and perfused with saline, followed by fixation
with 4% paraformaldehyde, before the tissue was processed for cryo-
sectioning. Cryosections of 30 mm were blocked free-floating with
blocking buffer (0.3 M glycine, 1% BSA, 5% normal donkey serum,
5% normal goat serum, 0.30% Triton X-100, Tris-buffered saline
[TBS]) for 1 h at room temperature, followed by primary antibody in-
cubation at 4C in blocking buffer for 24–72 h. After washing with
TBS, tissue was incubated with secondary antibodies at room temper-
ature for 1 h in blocking solution and washed again in TBS. Tissue was
mounted with Prolong Gold antifade reagent cat. no. P36931 (Life
Technologies, Eugene, OR, USA). Primary antibodies used included
the following: GFAP (mouse [Ms]) cat. no. MAB3402 (EMD Milli-
pore, Darmstadt, Germany, 1:500 dilution), IBA1 (rabbit [Rb]) cat.
no. 019-19741 (Wako Pure Chemical Industries, Osaka, Japan,
1:1,000 dilution), NeuN (Ms) cat. no. MAB377 (EMD Millipore,
1:500 dilution), APC/CC1 (Ms) cat. no. OP80-100UG (EMD Milli-
pore, 1:50 dilution), P0 (chicken [Ck]) cat. no. PZ0 (Aves Labs, Ti-
gard, OR, USA, 1:250 dilution), MBP (rat [Rt]) cat. no. MAB386
(EMD Millipore, 1:100 dilution), LAMP1 (Rt) cat. no. sc-19992
(Santa Cruz Laboratories, Santa Cruz, CA, USA, 1:300 dilution)
PDGFR-a (Rb) cat. no. SC338 (Santa Cruz Biotechnology, Dallas,
TX, USA, 1:200 dilution), PCNA (Ms) cat. no. SC56 (Santa Cruz
Biotechnology, 1:500 dilution), Fibrinogen (Rb) cat. no. A0080 (Agi-
lent-Dako, Santa Clara, CA, USA, 1:200 dilution), PLP (Rt) (AA3
monoclocal hybridoma, 1:100 dilution), and isolectin-FITC cat. no.
L32478 (Thermo Fisher, 1:500 dilution). Secondary antibodies
included the following: Alexa Fluor 488 Anti-Mouse cat. no. A-
11029 (Thermo Fisher Scientific, 1:500 dilution), Dylight 488 Anti-
Rabbit cat. no. 211-482-171 (Jackson ImmunoResearch, West Grove,
PA, USA, 1:500 dilution), Cy3 Anti-Rabbit cat. no. 711-166-152
(Jackson ImmunoResearch, 1:500 dilution), Alexa Fluor 546 Anti-
Mouse cat. no. A11030 (Thermo Fisher Scientific, 1:500 dilution),
Dylight 549 Anti-Chicken cat. no. 003-500-003 (Jackson ImmunoR-
esearch, 1:500 dilution), Alexa Fluor 647 Anti-Mouse cat. no. A21236
(Thermo Fisher Scientific, 1:500 dilution), and Dylight 649 Anti-Rab-
bit cat. no. 211-492-171 (Jackson ImmunoResearch, 1:500 dilution).
Cell nuclei were stained with DAPI cat. no. D1306 (Thermo Fisher,
1:3,000 dilution in TBS). Immunofluorescent complexes were visual-
ized using a Leica TCS SPE confocal laser with an upright DM5500Q
Microscope (Leica Biosystems, Buffalo Grove, IL, USA).
Immunoblotting
Tissue was homogenized in 10 volumes of RIPA buffer cat. no.
BP-115x (Boston BioProducts, Ashland, MA, USA) using a Vibra-
cell ultrasonic liquid processor model number VCX 130 (Sonics
and Materials). Lysates were incubated at 4C with rocking for 1 h
and then spun at 14,000  g for 20 min. The supernatant was
removed, and its protein concentration quantified via a BCA assay
cat. no. 23225 (Thermo Fisher Scientific). A total of 12.5 mg protein
lysate was loaded into 10-well 4%–12% Bis-Tris Protein Gels,
1.5 mm, cat. no. NP0335BOX (Thermo Fisher Scientific). After gel
electrophoresis, protein transfer was made onto a polyvinylidene
fluoride (PVDF) membrane cat. no. 1620177 (Bio-Rad, Hercules,
CA, USA). Membranes were blocked with 5% milk/1% BSA in
TBS-Tween (0.5%) (TBS-T) for 1 h at room temperature. Primary
antibodies were diluted in 1% BSA/TBS-T and incubated at 4C over-
night. Secondary antibodies were diluted in 5%milk/TBS-T and incu-
bated on blot for 1 h at room temperature. Blots were visualized with
ECL reagent cat. no. 32106 (Thermo Fisher Scientific) on an Odyssey
Fc Imaging system (LI-COR, Lincoln, NE, USA). Primary antibodies
used included the following: actin (Rb) cat. no. A2066 (Sigma-Al-
drich, St. Louis, MO, USA, 1:1,000 dilution), LAMP1 (Rat) cat. no.
sc-199992 (Santa Cruz Laboratories, 1:500 dilution); PDGFR-a
(Rb) cat. no. SC338 (Santa Cruz Biotechnology, 1:200 dilution),
fibrinogen (Rb) cat. no. A0080 (Agilent-Dako, 1:200 dilution), Ser-
pina3 (Goat) cat. no. AF4709 (R&D Systems, Minneapolis, MN,
USA, 1:500 dilution), LCN2 (goat) cat. no. AF1857 (R&D Systems,
1:500 dilution); phosphoSMAD (Rb) cat. no. 06-702 (Upstate
Biotechnology, Lake Placid, NY, USA, 1:500 dilution); SMAD (Mo)
cat. no. 05-1459 (EMD Millipore, 1:200), MMP9 (Mo) cat. no. sc-
393859 (Santa Cruz Biotechnology, 1:500 dilution); occludin (Mo)
cat. no. 33-1500 (Thermo Fisher, 1:500 dilution); and claudin5 (Rb)
cat. no. SAB4502981 (EMD Millipore, 1:500 dilution).
Neuroglial cell culture and collection
P1–P5 TWI mice were anesthetized with 400 mg/kg tribromoethanol
before euthanasia. Neuroglial cells were isolated from the
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subventricular zone and hippocampus of P1–P5 TWI pups and put
into Earle’s Balanced Salt Solution (EBSS) cat. no. E6267 (Sigma-Al-
drich) containing 1 mg/mL papain cat. no. LS003126 (Worthington
Biochemical, Lakewood, NJ, USA), 0.2 mg/mL L-cysteine cat. no.
C7602 (Sigma-Aldrich), 0.2 mg/mL EDTA cat. no. 15575-038 (Life
Technologies), and 0.2 mg/mL DNase cat. no. L5002007 (Worthing-
ton Biochemical) and incubated at 37C for 45 min with gentle
rocking. Cells were then centrifuged at 123 g for 10 min and the su-
pernatant removed. Cells were resuspended in GIBCO Hank’s
Balanced Salt Solution (HBSS) cat. no. 13170-112 (Thermo Fisher
Scientific) with 100 U/mL GIBCO penicillin/streptomycin cat. no.
15140122 (Thermo Fisher Scientific) and 0.6% glucose and mechan-
ically dissociated by repeat pipetting. For proliferation, neuroglial
cells were grown in Neurocult Basal Medium (Mo and Rat) cat. no.
05700 (Stem Cell Technologies, Vancouver, BC, Canada) with
Neurocult Proliferation Supplement (Mo and Rat) cat. no. 05701
supplement (Stem Cell Technologies) and 100 U/mL penicillin/strep-
tomycin, 20 ng/mL human epidermal growth factor cat. no. AF-100-
15 (PeproTech, Rocky Hill, NJ, USA, 10 ng/mL), 20 ng/mL human
fibroblast growth factor cat. no. 100-18B (PeproTech, 10 ng/mL),
and 1 mg/mL heparin cat. no. H3393 (Sigma-Aldrich). Neuroglial cells
were cultured at 37C, 5% CO2, with daily perturbation to maintain
single-cell suspension. Cells were counted on a hemocytometer before
transduction with AAV9-GALC at a MOI of 5,000 vg/cell. Samples
were collected every 4 days by centrifugation at 800  g at 4C for
10 min following resuspension in 100 mL H2O for qPCR or H2O
with 1 protease and phosphatase inhibitor cat. no. 539134 (EMD
Millipore) and cat. no. 524625 (EMD Millipore), respectively, for
GALC activity quantification. Samples were then lysed using a VC
130 Vibra-cell ultrasonic liquid processor (Sonics and Materials).
DNA isolation and quantitative polymerase chain reaction
(qPCR)
An equivalent volume of (25:24:1) phenol/chloroform/isoamyl
alcohol (Invitrogen [Carlsbad, CA, USA] 1857C038, 4C #3) was
added to the cell lysate before vortexing for 10 s. Samples were then
centrifuged at 10,000  g at room temperature for 30 s. The aqueous
phase was transferred to a new tube and 1/10 volume of 3 M sodium
acetate, pH 5.2, was added before vortexing. A 2 volume of ice-cold
100% ethanol was added and vortexed before placing on dry ice for
5 min. Samples were centrifuged at 15,000  g at room temperature
for 5 min and the supernatant removed. Room temperature 70%
ethanol, 1 mL, was added before vortexing and centrifugation at
15,000  g at room temperature for 5 min. The supernatant was dis-
carded and samples were air dried for 15 min to allow any remaining
ethanol to evaporate. The samples were resuspended in 50 mL TE
buffer and quantified on a Nanodrop ND-1000 spectrophotometer
(Thermo Fisher Scientific). 96-Well Clear PCR plates cat. no.
MLL9601 were filled with 10 mL iTaq Universal SYBR Green Super-
mix cat. no. 172512 (BioRad), 0.4 mL 10 mM forward primer, 0.4 mL
10 mM reverse primer, 3 mL 20 ng/mL DNA, and 6.2 mL H2O. AAV
primers are as follows: forward 50-TTGCTCTGACTGATGGCTTG-
30 and reverse 50-CCACACCTGCAGCTCTTGTA-30. Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) primers are as follows:
forward 50-CATCACTGCCACCCAGAAGACTG-30 and reverse 50-
ATGCCAGTGAGCTTCCCGTTCAG-30. qPCR was performed on
a CFX Connect Real Time PCR Optics Module (BioRad) with the
following settings: 95C for 2 min, then 40 cycles of 95C for 10 s,
then 50.3C for 30 s, and ending with a gradual increase from 65C
to 95C.
GFP fluorescence quantification
Animals were anesthetized perfused with saline followed by post-
fixing brains in PBS with 4% paraformaldehyde (PFA) for 48 h. Brains
were then cryosectioned at 30 mm on a SM2010R sliding microtome
(Leica Biosystems). Tile-scanned images were taken on a LSM 880
confocal microscope with 20 air objective lens (Carl Zeiss AG, Jena,
Germany). Collection parameters were as follows: excitation at
488 nm from an argon laser, 4% laser power, and 2.8 mm thickness.
Every other section from each animal was analyzed to find the section
with the highest fluorescence for comparison. The images with the
highest fluorescence were then quantified in ImageJ (National Insti-
tutes of Health [NIH], Bethesda, MD, USA).
Electron microscopy
Animals were anesthetized before perfusion with heparinized PBS
(0.09 mg/mL) and tissue was then removed and fixed with 3% para-
formaldehyde/2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4)
for 12 h at 4C. The tissue was then transferred to 4% paraformalde-
hyde/1% glutaraldehyde in 0.1M cacodylate buffer (pH 7.4) until pro-
cessed for EM. For EM, the tissue was embedded in araldite, and
ultrathin sections prepared and stained as described.80
Statistical analysis
Statistics and graphs were prepared with Prism 8 software (GraphPad
Software, La Jolla, CA, USA). Data were analyzed using a one-way
ANOVA with a Tukey’s post hoc analysis, with p <0.05 considered
significant. Graphs represent the mean of independent measurements
with error bars representing the standard error of the mean. All
immunoblotting was performed with technical replicates of at least
3. Variation was comparable between groups.
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S1. AAV therapy protects PNS myelination. Sciatic nerve tissue was stained with MBP 
(green) and P0 (red) to examine myelination within the PNS. Myelination in sciatic nerves 
at P40 and in aged TWI+AVV was largely preserved in TWI+AAV (E-H) as compared to 
WT (C,D). Sham P40 TWI nerves (A-B) show extensive myelin loss. Scale bar A-H: 1 
mm. 
S2. Spinal cords of aged treated TWI are devoid of demyelinating plaques. Serial 
sections of spinal cord were stained with MBP (red). Pathological analysis of focal lesions 
or significant pathological changes were not detected in cords of aged TWI+AAV and 
TWI-AAV+BMT. Scale bar 0.5 mm. 
S3. Locomotor ability and Tremor in aged treated TWI. Locomotor function (A) was 
measured, and presence of tremor (B) was determined twice a week until 20 weeks and 
then once per week thereafter. Locomotor ability was scored as follows: normal-0, 
waddling-1, partial paralysis-1.5, and full paralysis-2. Tremor was scored as no tremor-0 
or tremor present-1. This revealed that tremor develops in most treated animals at 16 
weeks and locomotor ability shows signs of decline at 20 weeks. (sham TWI n=25, WT 
n=7, TWI-AAV n=5, TWI-AAV+BMT n = 8) 
S4. Interlaboratory cross-examination of late-onset multi-focal demyelination in 
aged treated TWI. Tissue from P160 WT (A), sham P35 TWI (B), and TWI treated with 
a combination of AAV9-GALC, BMT, and L-Cycloserine (Cyc) (C-F) were immunostained 
for MBP. At P35 (C) treated animals exhibit healthy myelination comparable to the WT. 
At P160 (D) and later aged (>400 days of age) timepoints (E,F) the animals show 
multifocal demyelination (dotted circle and arrows). Images provided by Dr. Marks Sands. 
Scale Bar A-F: 50 m.  
S5. Spinal cords from treated TWI lack leakage of plasma proteins. Serial spinal cord 
sections were stained for IgG (red) (a general read out protein of plasma extravasation) 
and IBA1 (green). IgG and microglia were undetectable within spinal cords of aged 
TWI+AAV. Sham TWI and aged WT also exhibited no IgG but, in contrast, sham TWI 
contained extensive microgliosis. Scale bar 0.5 mm. 
 





